Literature DB >> 19026722

Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets.

Laure Bachelet1, Isabelle Bertholon, Damien Lavigne, Roger Vassy, Martine Jandrot-Perrus, Frédéric Chaubet, Didier Letourneur.   

Abstract

BACKGROUND: P-selectin is an adhesion receptor expressed on activated platelets and endothelial cells. Its natural ligand, P-selectin glycoprotein ligand-1, is expressed on leucocytes and the P-selectin/PSGL-1 interaction is involved in leukocyte rolling. We have compared the interaction of P-selectin with several low molecular weight polysaccharides: fucoidan, heparin and dextran sulfate.
METHODS: Binding assays were obtained from the interaction of the polysaccharides with Sialyl Lewis X and PSGL-1 based constructs onto microtiter plates coated with P-selectin. SELDI TOF mass spectrometry was performed with anionic chips arrays coated with P-selectin in the absence or in the presence of polysaccharides. Kd were obtained from surface plasmon resonance experiments with immobilized P-selectin constructs, polysaccharides being injected in the mobile phase. Human whole blood flow cytometry experiments were performed with fluorescein isothiocyanate labelled polysaccharides with or without platelets activators.
RESULTS: The fucoidan prevented P-selectin binding to Sialyl Lewis X with an IC(50) of 20 nM as compared to 400 nM for heparin and <25000 nM for dextran sulfate. It exhibited the highest affinity for immobilized P-selectin with a KD of 1.2 nM, two orders of magnitude greater than the K(D) of the other polysaccharides. Mass spectrometry evidenced the formation of a complex between P-selectin and fucoidan. The intensity of the fucoidan binding to platelets was dependent on the level of platelet activation. Competition between fucoidan and an anti P-selectin antibody demonstrated the specificity of the interaction. GENERAL SIGNIFICANCE: Low molecular weight fucoidan is a promising therapeutic agent of natural origin for biomedical applications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026722     DOI: 10.1016/j.bbagen.2008.10.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  27 in total

1.  P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

Authors:  Yosi Shamay; Moshe Elkabets; Hongyan Li; Janki Shah; Samuel Brook; Feng Wang; Keren Adler; Emily Baut; Maurizio Scaltriti; Prakrit V Jena; Eric E Gardner; John T Poirier; Charles M Rudin; José Baselga; Adriana Haimovitz-Friedman; Daniel A Heller
Journal:  Sci Transl Med       Date:  2016-06-29       Impact factor: 17.956

2.  Sulfation modulates the targeting properties of hyaluronic acid to P-selectin and CD44.

Authors:  Deep S Bhattacharya; Denis Svechkarev; Aishwarya Bapat; Prathamesh Patil; Michael A Hollingsworth; Aaron M Mohs
Journal:  ACS Biomater Sci Eng       Date:  2020-05-04

3.  Early Detection of Localized Immunity in Experimental Autoimmune Myocarditis Using [99mTc]Fucoidan SPECT.

Authors:  Jonathan Vigne; Thomas Cognet; Kevin Guedj; Marion Morvan; Olivier Merceron; Liliane Louedec; Christine Choqueux; Antonino Nicoletti; Brigitte Escoubet; Frederic Chaubet; Jean-Baptiste Michel; François Rouzet
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

4.  Anti-Proliferation Activity of Fucoidan in MKN45 Gastric Cancer Cells and Downregulation of Phosphorylated ASK1, a Cell Cycle-Regulated Kinase.

Authors:  Miwa Yoshimoto; Katsumi Higaki; Eiji Nanba; Masahide Ikeguchi
Journal:  Yonago Acta Med       Date:  2015-03-27       Impact factor: 1.641

5.  Thrombosis: Novel nanomedical concepts of diagnosis and treatment.

Authors:  Iwona Cicha
Journal:  World J Cardiol       Date:  2015-08-26

6.  Over-sulfated glycosaminoglycans are alternative selectin ligands: insights into molecular interactions and possible role in breast cancer metastasis.

Authors:  Pierre Martinez; Gérard Vergoten; Florent Colomb; Marie Bobowski; Agata Steenackers; Mathieu Carpentier; Fabrice Allain; Philippe Delannoy; Sylvain Julien
Journal:  Clin Exp Metastasis       Date:  2013-06-06       Impact factor: 5.150

7.  Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.

Authors:  Neeta Bala Tannan; Mandana T Manzari; Laurie Herviou; Mariana Da Silva Ferreira; Connor Hagen; Hiroto Kiguchi; Katia Manova-Todorova; Venkatraman Seshan; Elisa de Stanchina; Daniel A Heller; Anas Younes
Journal:  Blood       Date:  2021-04-15       Impact factor: 22.113

8.  Targeted drug delivery strategies for precision medicines.

Authors:  Mandana T Manzari; Yosi Shamay; Hiroto Kiguchi; Neal Rosen; Maurizio Scaltriti; Daniel A Heller
Journal:  Nat Rev Mater       Date:  2021-02-02       Impact factor: 66.308

9.  Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer.

Authors:  Allison N DuRoss; Madeleine R Landry; Charles R Thomas; Megan J Neufeld; Conroy Sun
Journal:  Cancer Lett       Date:  2020-11-21       Impact factor: 9.756

Review 10.  Polysaccharide nanosystems for future progress in cardiovascular pathologies.

Authors:  Amanda Karine Andriola Silva; Didier Letourneur; Cédric Chauvierre
Journal:  Theranostics       Date:  2014-03-11       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.